Effects of β‐adrenergic blockade in an osteoblast‐like cell line

R. J. Majeska, Barbara Minkowitz, W. Bastian, T. A. Einhorn

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The β‐adrenergic blocking agent propranolol was shown in previous studies to increase orthotopic bone formation in rats. To understand the cellular mechanisms underlying this observation, propranolol was tested for its effects on osteoblastic cells, which posses adenylate cyclase‐coupled β‐adrenergic receptors. The ability of propranolol to modulate parathyroid hormone (PTH) and isoproterenol effects on adenylate cyclase activity and on alkaline phosphatase expression was studied in the osteoblast‐like rat osteosarcoma cell line ROS 17/2.8. At concentrations between 0.1 and 10 μM, DL‐propranolol specifically inhibited adenylate cyclase stimulation by the β‐adrenergic agonist isoproterenol, but did not alter either basal or PTH‐stimulated activity. At these concentrations, propranolol also blunted the inhibition of alkaline phosphatase activity by isoproterenol but not PTH. Propranolol alone had minimal effects on ROS alkaline phosphatase activity at low concentrations (0.1–1 μM), but became inhibitory at high concentrations (10–100 μM). Thus, the direct effects of physiologically relevant propranolol concentrations on osteoblastic cells can be attributed principally to β‐adrenergic blockade. These findings further suggest that propranolol may enhance bone formation by preserving osteoblastic activity in the face of inhibition by β‐adrenergic agonists.

Original languageEnglish (US)
Pages (from-to)379-384
Number of pages6
JournalJournal of Orthopaedic Research
Volume10
Issue number3
DOIs
StatePublished - Jan 1 1992
Externally publishedYes

Fingerprint

Propranolol
Adrenergic Agents
Cell Line
Isoproterenol
Alkaline Phosphatase
Adrenergic Agonists
Parathyroid Hormone
Adenylyl Cyclases
Osteogenesis
Adrenergic Antagonists
Osteosarcoma
Adrenergic Receptors

All Science Journal Classification (ASJC) codes

  • Orthopedics and Sports Medicine

Cite this

Majeska, R. J. ; Minkowitz, Barbara ; Bastian, W. ; Einhorn, T. A. / Effects of β‐adrenergic blockade in an osteoblast‐like cell line. In: Journal of Orthopaedic Research. 1992 ; Vol. 10, No. 3. pp. 379-384.
@article{89e0ce2045a340679caaea48dd171d46,
title = "Effects of β‐adrenergic blockade in an osteoblast‐like cell line",
abstract = "The β‐adrenergic blocking agent propranolol was shown in previous studies to increase orthotopic bone formation in rats. To understand the cellular mechanisms underlying this observation, propranolol was tested for its effects on osteoblastic cells, which posses adenylate cyclase‐coupled β‐adrenergic receptors. The ability of propranolol to modulate parathyroid hormone (PTH) and isoproterenol effects on adenylate cyclase activity and on alkaline phosphatase expression was studied in the osteoblast‐like rat osteosarcoma cell line ROS 17/2.8. At concentrations between 0.1 and 10 μM, DL‐propranolol specifically inhibited adenylate cyclase stimulation by the β‐adrenergic agonist isoproterenol, but did not alter either basal or PTH‐stimulated activity. At these concentrations, propranolol also blunted the inhibition of alkaline phosphatase activity by isoproterenol but not PTH. Propranolol alone had minimal effects on ROS alkaline phosphatase activity at low concentrations (0.1–1 μM), but became inhibitory at high concentrations (10–100 μM). Thus, the direct effects of physiologically relevant propranolol concentrations on osteoblastic cells can be attributed principally to β‐adrenergic blockade. These findings further suggest that propranolol may enhance bone formation by preserving osteoblastic activity in the face of inhibition by β‐adrenergic agonists.",
author = "Majeska, {R. J.} and Barbara Minkowitz and W. Bastian and Einhorn, {T. A.}",
year = "1992",
month = "1",
day = "1",
doi = "10.1002/jor.1100100310",
language = "English (US)",
volume = "10",
pages = "379--384",
journal = "Journal of Orthopaedic Research",
issn = "0736-0266",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

Effects of β‐adrenergic blockade in an osteoblast‐like cell line. / Majeska, R. J.; Minkowitz, Barbara; Bastian, W.; Einhorn, T. A.

In: Journal of Orthopaedic Research, Vol. 10, No. 3, 01.01.1992, p. 379-384.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of β‐adrenergic blockade in an osteoblast‐like cell line

AU - Majeska, R. J.

AU - Minkowitz, Barbara

AU - Bastian, W.

AU - Einhorn, T. A.

PY - 1992/1/1

Y1 - 1992/1/1

N2 - The β‐adrenergic blocking agent propranolol was shown in previous studies to increase orthotopic bone formation in rats. To understand the cellular mechanisms underlying this observation, propranolol was tested for its effects on osteoblastic cells, which posses adenylate cyclase‐coupled β‐adrenergic receptors. The ability of propranolol to modulate parathyroid hormone (PTH) and isoproterenol effects on adenylate cyclase activity and on alkaline phosphatase expression was studied in the osteoblast‐like rat osteosarcoma cell line ROS 17/2.8. At concentrations between 0.1 and 10 μM, DL‐propranolol specifically inhibited adenylate cyclase stimulation by the β‐adrenergic agonist isoproterenol, but did not alter either basal or PTH‐stimulated activity. At these concentrations, propranolol also blunted the inhibition of alkaline phosphatase activity by isoproterenol but not PTH. Propranolol alone had minimal effects on ROS alkaline phosphatase activity at low concentrations (0.1–1 μM), but became inhibitory at high concentrations (10–100 μM). Thus, the direct effects of physiologically relevant propranolol concentrations on osteoblastic cells can be attributed principally to β‐adrenergic blockade. These findings further suggest that propranolol may enhance bone formation by preserving osteoblastic activity in the face of inhibition by β‐adrenergic agonists.

AB - The β‐adrenergic blocking agent propranolol was shown in previous studies to increase orthotopic bone formation in rats. To understand the cellular mechanisms underlying this observation, propranolol was tested for its effects on osteoblastic cells, which posses adenylate cyclase‐coupled β‐adrenergic receptors. The ability of propranolol to modulate parathyroid hormone (PTH) and isoproterenol effects on adenylate cyclase activity and on alkaline phosphatase expression was studied in the osteoblast‐like rat osteosarcoma cell line ROS 17/2.8. At concentrations between 0.1 and 10 μM, DL‐propranolol specifically inhibited adenylate cyclase stimulation by the β‐adrenergic agonist isoproterenol, but did not alter either basal or PTH‐stimulated activity. At these concentrations, propranolol also blunted the inhibition of alkaline phosphatase activity by isoproterenol but not PTH. Propranolol alone had minimal effects on ROS alkaline phosphatase activity at low concentrations (0.1–1 μM), but became inhibitory at high concentrations (10–100 μM). Thus, the direct effects of physiologically relevant propranolol concentrations on osteoblastic cells can be attributed principally to β‐adrenergic blockade. These findings further suggest that propranolol may enhance bone formation by preserving osteoblastic activity in the face of inhibition by β‐adrenergic agonists.

UR - http://www.scopus.com/inward/record.url?scp=0026864104&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026864104&partnerID=8YFLogxK

U2 - 10.1002/jor.1100100310

DO - 10.1002/jor.1100100310

M3 - Article

C2 - 1349041

AN - SCOPUS:0026864104

VL - 10

SP - 379

EP - 384

JO - Journal of Orthopaedic Research

JF - Journal of Orthopaedic Research

SN - 0736-0266

IS - 3

ER -